Soligenix, Inc. Common Stock (SNGX) — Analysis Summary
Soligenix, Inc. Common Stock (SNGX) has a market cap of $7.65M with year-over-year revenue growth of +0.0%. Net margin stands at -9282.3%. The stock trades at a P/E ratio of -0.7.
Key Takeaways
- Revenue changed +0.0% year-over-year
- Net margin of -9282.3%
- P/E ratio of -0.7
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, SNGX posted revenue growth of +0.0% and trades at a P/E of -0.7.
Soligenix, Inc. Common Stock (SNGX)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Revenue fell 100.0% vs the prior period.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Sector
PHARMACEUTICAL PREPARATIONS
Employees
14
Headquarters
PRINCETON, NJ
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.